Lab-Grown Heart Valve Cells: Indian Researchers Achieve Major Breakthrough in Cardiac Regenerative Medicine

LUCKNOW, India — In a major step forward for regenerative cardiac medicine, researchers at the Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) have successfully isolated and cultured human valve interstitial cells (VICs) in a laboratory environment.

The milestone, announced in July 2026, was achieved by a multidisciplinary team led by Dr. Shantanu Pande from the Department of Cardiovascular and Thoracic Surgery (CVTS) and Dr. Alok Kumar from the Department of Molecular Medicine and Biotechnology. By cultivating living human valve tissue from patient samples, the team has laid the foundation for developing bioengineered replacement valves. This advancement holds immediate promise for mapping the precise pathways of cardiac scarring and offers long-term hope for millions suffering from severe valvular damage—particularly those impacted by rheumatic heart disease (RHD).

Harvesting Life from Discarded Tissue

The human heart valve relies heavily on valve interstitial cells (VICs)—specialized biological units nestled within the tissue matrix that maintain structural flexibility, preserve mechanical strength, and repair everyday cellular wear and tear. When VICs malfunction or become chronically inflamed, the valve tissue stiffens, calcium builds up, and blood flow becomes severely compromised.

To isolate these essential cells, the SGPGIMS research team established a protocol centered on patient consent and tissue preservation. Rather than allowing damaged valve tissue to be discarded following routine valve replacement procedures, surgeons transferred the samples directly to biotechnology specialists.

“The tissue was used to isolate valve interstitial cells and grow new living cells in the laboratory,” explained Prof. Pande. Culturing these cells in controlled petri dishes allows scientists to observe live human valve biology without risking patient safety, creating an accurate biological platform to study how structural damage unfolds over time.

Targeting the Burden of Rheumatic Heart Disease

While degenerative valve disease is common in aging western populations, this research carries immediate relevance for public health in India, where rheumatic heart disease (RHD) remains a formidable challenge.

RHD originates as a simple bacterial infection—streptococcal pharyngitis, or “strep throat.” If left untreated with basic antibiotics, the immune system’s response can trigger rheumatic fever, leading to chronic, irreversible scarring of the heart valves.

Statistical Snapshot: The Global & Local RHD Burden

• Global Concentration: India accounts for 40% to 50% of all global RHD cases and 30% to 40% of RHD-related deaths.

• Pediatric Prevalence: School-level screenings in India reveal an RHD prevalence of 1 to 5 per 1,000 children.

• Regional Impact: In Uttar Pradesh, local estimates range from 0.5 to 4.5 per 1,000 children.

Because RHD disproportionately strikes children and young adults, affected patients frequently require mechanical or bioprosthetic valve replacements early in life. Current artificial replacements do not grow alongside a developing child, often forcing pediatric patients to undergo multiple invasive open-heart operations as they mature.

Unveiling the Molecular Cascades of Scarring

By monitoring the lab-grown VICs, the SGPGIMS team successfully mapped two distinct biological communication pathways that drive inflammation and progressive fibrosis (tissue stiffening) in diseased valves.

[Cellular Trigger] ──> TGF-β / SMAD3 Pathway ──> Overactive Healing ──> Tissue Fibrosis (Scarring)
                   └──> ERK 1/2 Pathway       ──> Altered Proliferation ──> Valve Stiffening & Failure

1. The TGF-β / SMAD3 Cascade: Transforming Growth Factor-beta (TGF-β) works alongside its intracellular messenger, SMAD3, to repair damaged tissue. However, Dr. Alok Kumar noted that when this pathway remains continuously active, it overstimulates cellular repair, causing dense tissue scarring.

2. The ERK 1/2 Messenger Network: Extracellular Signal-Regulated Kinases (ERK 1/2) are enzymes that signal cells when to divide, grow, and anchor themselves. “We now know that in RHD patients, this pathway aids scarring and eventually damages the valve by stiffening it,” Dr. Kumar stated.

Identifying these precise signaling cascades gives pharmacological researchers specific molecular targets. Blocking or modulating these enzymes with novel drugs could potentially slow or arrest valve stiffening before irreversible surgical damage occurs.

From the Dish to the Clinic: Promises and Limitations

The ultimate goal of cardiovascular tissue engineering is to create fully living, bioengineered valves. Such tissue-engineered valves would seamlessly integrate into the patient’s body, self-repair, and grow naturally with pediatric recipients.

Despite the optimism surrounding the SGPGIMS milestone, translating cellular culture into clinical implants requires overcoming several critical engineering barriers:

• Mass Cell Production: Scaling up cell cultures from millions to billions of viable VICs without inducing premature cellular fatigue or genetic mutation.

• Biocompatible Scaffolds: Engineering 3D porous, biodegradable matrices that guide cells to form precise leaflet shapes while dissolving safely over time.

• Mechanical Endurance: Ensuring lab-grown valves can immediately endure the immense physical stress of the human circulatory system—opening and closing roughly 100,000 times per day under high fluid pressures.

• Regulatory & Safety Rigor: Navigating stringent clinical safety phases to rule out immune rejection or structural degradation in long-term human trials.

Independent tissue engineering experts note that while stem-cell approaches (such as induced pluripotent stem cells) are actively being explored globally, direct harvesting and expansion of primary VICs remains the gold standard for understanding true native valve behavior.

What This Means for Patients Today

For individuals currently diagnosed with heart valve disorders, standard surgical repair or replacement remains the necessary path of care. Bioengineered replacement valves remain in developmental phases and are not yet available for clinical transplantation.

However, the discovery of the TGF-β and ERK 1/2 pathways offers near-term promise. Medicinal chemists can now utilize these laboratory cell models to test experimental compounds capable of halting scarring. In the long run, slowing down valve deterioration could delay surgical timelines by years or decades.

On a broader scale, this breakthrough highlights a vital public health truth: preventing RHD starts with basic care. Promptly treating sore throats with antibiotics prevents rheumatic fever entirely, protecting delicate heart valves from taking the first step toward permanent damage.

Research & Institutional Support

This study was conducted at SGPGIMS, Lucknow, with institutional leadership from Director Prof. R.K. Dhiman. The multidisciplinary research team included key contributions from Charan Sai Ramireddi and Anjali Singh (Molecular Medicine and Biotechnology), Mohit K. Rai and Vikas Agarwal (Clinical Immunology), Prof. S.K. Agarwal (CVTS), and Dr. Vinita Agrawal (Pathology). The research was supported by funding from the Department of Biotechnology (DBT), Government of India.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. ET HealthWorld. SGPGIMS researchers isolate, grow human heart valve cells in lab. Published July 27, 2026. https://health.economictimes.indiatimes.com/news/industry/sgpgims-researchers-isolate-grow-human-heart-valve-cells-in-lab/132676605

2. The Times of India. SGPGIMS researchers isolate, grow human heart valve cells in lab. Published July 27, 2026. https://timesofindia.indiatimes.com/city/lucknow/sgpgims-researchers-isolate-grow-human-heart-valve-cells-in-lab/articleshow/132676605.cms